Anti-Mouse TNFα – Purified in vivo GOLD™ Functional Grade

Pricing & Details

Product No.T258
Clone
TN3-19.12
Protein
Tumor Necrosis Factor-Alpha
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Tumor Necrosis Factor Ligand Superfamily Member 2 (TNFSF2), Cachectin, Differentiation-Inducing Factor (DIF), Necrosin, Cytotoxin
Isotype
Armenian Hamster
IgG
Applications
IP
,
N
,
WB
Prod No.
Size
Price
Avail.
Qty
Add to cart
T258-1.0 mg
1.0 mg
$105.00
$81.90
In stock
Max:
Min: 1
Step: 1
T258-5.0 mg
5.0 mg
$355.00
$276.90
In stock
Max:
Min: 1
Step: 1
T258-25 mg
25 mg
$965.00
$752.70
In stock
Max:
Min: 1
Step: 1
T258-50 mg
50 mg
$1,595.00
$1,244.10
In stock
Max:
Min: 1
Step: 1
T258-100 mg
100 mg
$2,300.00
$1,794.00
In stock
Max:
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Data

Antibody Details

Product Details

Reactivity Species
Mouse
Host Species
Armenian Hamster
Immunogen
Recombinant mouse TNFα
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
ELISA: Each lot of this antibody is quality control tested by ELISA assay. For use of this antibody as a capture, a concentration range of 2 - 6 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of mouse TNF-α recombinant protein ranging from 500 to 4 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.
Additional Reported Applications For Relevant Conjugates ?
N: Clone TN3-19.12 has been shown to neutralize murine TNFα
WB
IP
FC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Armenian Hamster Anti-Mouse TNFa (Clone TN3-19.12 ) recognizes Mouse TNFa. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution
Activated monocytes, neutrophils, macrophages, T cells, B cells, NK cells, LAK cells
Background
The tumor necrosis factor (TNF-alpha) is a multifaceted polypeptide cytokine known as a mediator of inflammation and immunity.1 It may mediate some of the significant changes in cellular homeostasis which accompany the invasion of the mammalian host by viruses, bacteria, and parasites.2 TNF-α is an acute phase protein which initiates a cascade of cytokines and increases vascular permeability, thereby recruiting macrophage and neutrophils to a site of infection. TNF-α secreted by the macrophage causes blood clotting which serves to contain the infection. TNF-α has been detected in synovial fluid of patients with rheumatoid arthritis. Clone TN3-19.12 antibody can neutralize the bioactivity of natural or recombinant TNF-α

Antigen Details

NCBI Gene Bank ID
Research Area
Immunology
.
Innate Immunity

References & Citations

1.) El-Harith el-HA et al. (2004) Saudi Med J. 25: 135
2.) Adolf GR et al. (1990) Infec Immun. 58: 3996
3.) Czepielewski, R. et al. (2021) Immunity 54(12):2795-2811.e9 Journal Link
Immunoprecipitation Protocol
General Western Blot Protocol